Eisai initiates rolling submission for Leqembi autoinjector BLA to FDA
BioArctic AB's partner Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb ... Read More
AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease
AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 ... Read More